These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 8183542)

  • 1. [Nephropathy in patients treated with ifosfamide].
    Kiss K; Nagy K; Hunyadi K; Simkó R
    Orv Hetil; 1994 May; 135(19):1023-6. PubMed ID: 8183542
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ifosfamide-induced renal tubular dysfunction and rickets in children with Wilms tumor.
    Burk CD; Restaino I; Kaplan BS; Meadows AT
    J Pediatr; 1990 Aug; 117(2 Pt 1):331-5. PubMed ID: 2166154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Ifosfamide-induced nephrotoxicity].
    Rossi R; Rath B; Ullrich K; Ehrich JH
    Monatsschr Kinderheilkd; 1993 Jul; 141(7):594-601. PubMed ID: 8413339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renal function after ifosfamide, carboplatin and etoposide (ICE) chemotherapy, nephrectomy and radiotherapy in children with Wilms tumour.
    Daw NC; Gregornik D; Rodman J; Marina N; Wu J; Kun LE; Jenkins JJ; McPherson V; Wilimas J; Jones DP
    Eur J Cancer; 2009 Jan; 45(1):99-106. PubMed ID: 18996004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The development of rickets as a complication of chemotherapy for the treatment of Wilms' tumor.
    Segal LS; Palumbo RC; Robertson WW
    Orthopedics; 1995 Mar; 18(3):261-4. PubMed ID: 7761316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ifosfamide-induced nephrotoxicity in 593 sarcoma patients: a report from the Late Effects Surveillance System.
    Stöhr W; Paulides M; Bielack S; Jürgens H; Treuner J; Rossi R; Langer T; Beck JD
    Pediatr Blood Cancer; 2007 Apr; 48(4):447-52. PubMed ID: 16628552
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk factors for nephrotoxicity after ifosfamide treatment in children: a UKCCSG Late Effects Group study. United Kingdom Children's Cancer Study Group.
    Skinner R; Cotterill SJ; Stevens MC
    Br J Cancer; 2000 May; 82(10):1636-45. PubMed ID: 10817497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renal dysfunctions secondary to ifosfamide treatment in children.
    Tokuc G; Yalçiner A; Kebudi R; Dogan S; Görgün O; Ayan I
    J Exp Clin Cancer Res; 1997 Jun; 16(2):227-30. PubMed ID: 9261752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rickets--a complication of ifosfamide chemotherapy for Wilms tumor.
    Relf M; Boal DK
    Pediatr Radiol; 1992; 22(3):209-10. PubMed ID: 1324461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of ifosfamide-induced nephrotoxicity: prospective follow-up in 75 patients.
    Rossi R; Pleyer J; Schäfers P; Kuhn N; Kleta R; Deufel T; Jürgens H
    Med Pediatr Oncol; 1999 Mar; 32(3):177-82. PubMed ID: 10064184
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ifosfamide, Fanconi's syndrome, and rickets.
    Pratt CB; Meyer WH; Jenkins JJ; Avery L; McKay CP; Wyatt RJ; Hancock ML
    J Clin Oncol; 1991 Aug; 9(8):1495-9. PubMed ID: 1649270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renal failure does not preclude cure in children receiving chemotherapy for Wilms tumor: a report from the National Wilms Tumor Study Group.
    Feusner JH; Ritchey ML; Norkool PA; Takashima JR; Breslow NE; Green DM
    Pediatr Blood Cancer; 2008 Feb; 50(2):242-5. PubMed ID: 17458877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Nephrotoxicity of ifosfamide with special reference to Fanconi Syndrome].
    Rogowska E; Woźniak W
    Med Wieku Rozwoj; 2004; 8(2 Pt 1):289-95. PubMed ID: 15738605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unilateral nephrectomy and cisplatin as risk factors of ifosfamide-induced nephrotoxicity: analysis of 120 patients.
    Rossi R; Gödde A; Kleinebrand A; Riepenhausen M; Boos J; Ritter J; Jürgens H
    J Clin Oncol; 1994 Jan; 12(1):159-65. PubMed ID: 8270973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potentiation of ifosfamide neurotoxicity, hematotoxicity, and tubular nephrotoxicity by prior cis-diamminedichloroplatinum(II) therapy.
    Goren MP; Wright RK; Pratt CB; Horowitz ME; Dodge RK; Viar MJ; Kovnar EH
    Cancer Res; 1987 Mar; 47(5):1457-60. PubMed ID: 3815347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A systematic review of the accuracy and utility of early markers of Ifosfamide-induced proximal tubulopathy in survivors of childhood cancers.
    Phillips RS; Tyerman K; Al-Kassim MI; Picton S
    Pediatr Hematol Oncol; 2008 Mar; 25(2):107-13. PubMed ID: 18363176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A prospective study on nephrotoxicity induced by continuous infusion of high-dose ifosfamide (15/m2)].
    Ferrari S; Zolezzi C; Bacci G; Pieretti F; Iantorno D; Figus E; Pizzoferrato A
    Minerva Pediatr; 1997; 49(1-2):29-37. PubMed ID: 9132558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A prospective evaluation of ifosfamide-related nephrotoxicity in children and young adults.
    Ho PT; Zimmerman K; Wexler LH; Blaney S; Jarosinski P; Weaver-McClure L; Izraeli S; Balis FM
    Cancer; 1995 Dec; 76(12):2557-64. PubMed ID: 8625085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Growth impairment after ifosfamide-induced nephrotoxicity in children.
    Stöhr W; Patzer L; Paulides M; Kremers A; Beck JD; Langer T; Rossi R
    Pediatr Blood Cancer; 2007 May; 48(5):571-6. PubMed ID: 16755549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic ifosfamide nephrotoxicity in children.
    Skinner R
    Med Pediatr Oncol; 2003 Sep; 41(3):190-7. PubMed ID: 12868118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.